Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1

In the phase 3 BRIGHTE study in heavily treatment-experienced adults with multidrug-resistant HIV-1, fostemsavir plus optimized background therapy (OBT) resulted in sustained rates of virologic suppression through 96 weeks. HIV-1 RNA <40 copies/mL was achieved in 163/272 (60%) Randomized Cohort (...

Descripción completa

Detalles Bibliográficos
Autores principales: Gartland, Margaret, Cahn, Pedro, DeJesus, Edwin, Diaz, Ricardo Sobhie, Grossberg, Robert, Kozal, Michael, Kumar, Princy, Molina, Jean-Michel, Mendo Urbina, Fernando, Wang, Marcia, Du, Fangfang, Chabria, Shiven, Clark, Andrew, Garside, Louise, Krystal, Mark, Mannino, Frank, Pierce, Amy, Ackerman, Peter, Lataillade, Max
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9211436/
https://www.ncbi.nlm.nih.gov/pubmed/35502922
http://dx.doi.org/10.1128/aac.01751-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9211436/
https://www.ncbi.nlm.nih.gov/pubmed/35502922
http://dx.doi.org/10.1128/aac.01751-21

Ejemplares similares